About Modus Therapeutics
Modus Therapeutics is a company based in Stockholm (Sweden) founded in 2011.. Modus Therapeutics has raised $22.88 million across 4 funding rounds from investors including Vinnova, Praktikertjänst and Healthcap. Modus Therapeutics offers products and services including Sevuparin. Modus Therapeutics operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Kedrion and Dova Pharmaceuticals, among others.
- Headquarter Stockholm, Sweden
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Modus Therapeutics Ab
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$22.88 M (USD)
in 4 rounds
-
Latest Funding Round
$3.47 M (USD), Series B
Jul 15, 2021
-
Investors
Vinnova
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Modus Therapeutics
Modus Therapeutics offers a comprehensive portfolio of products and services, including Sevuparin. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for sepsis and inflammatory disorders in patients.
Funding Insights of Modus Therapeutics
Modus Therapeutics has successfully raised a total of $22.88M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $3.47 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $3.5M
-
First Round
First Round
(02 Nov 2012)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Series B - Modus Therapeutics | Valuation |
investors |
|
| Jul, 2018 | Amount | Series B - Modus Therapeutics | Valuation | Healthcap |
|
| Feb, 2017 | Amount | Series A - Modus Therapeutics | Valuation | The Foundation for Baltic and East European Studies , Praktikertjänst |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Modus Therapeutics
Modus Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Vinnova, Praktikertjänst and Healthcap. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Research funding is provided for Baltic and Eastern European studies.
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided to Swedish companies across sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Modus Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Modus Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Modus Therapeutics Comparisons
Competitors of Modus Therapeutics
Modus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Kedrion and Dova Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for sickle cell disease treatment.
|
|
| domain | founded_year | HQ Location |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| domain | founded_year | HQ Location |
Drug candidates for rare diseases are acquired, developed, and commercialized.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Modus Therapeutics
Frequently Asked Questions about Modus Therapeutics
When was Modus Therapeutics founded?
Modus Therapeutics was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Where is Modus Therapeutics located?
Modus Therapeutics is headquartered in Stockholm, Sweden.
Who is the current CEO of Modus Therapeutics?
Ellen K Donnelly is the current CEO of Modus Therapeutics.
Is Modus Therapeutics a funded company?
Modus Therapeutics is a funded company, having raised a total of $22.88M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.59M, raised on Nov 02, 2012.
What does Modus Therapeutics do?
Founded in 2011 in Stockholm, Sweden, Modus Therapeutics operates in the biotechnology sector, focusing on therapies for hematologic disorders. Sevuparin, a proprietary polysaccharide drug, is being developed to address anti-adhesive and anti-inflammatory needs in Sickle Cell Disease patients. Orphan Drug Designations have been granted by the FDA and EMA for its use in restoring blood flow and reducing microvascular obstructions.
Who are the top competitors of Modus Therapeutics?
Modus Therapeutics's top competitors include GBT, Editas Medicine and Kedrion.
What products or services does Modus Therapeutics offer?
Modus Therapeutics offers Sevuparin.
Who are Modus Therapeutics's investors?
Modus Therapeutics has 4 investors. Key investors include Vinnova, Praktikertjänst, Healthcap, and Östersjöstiftelsen.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.